Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 2,314

Document Document Title
WO/2022/166974A1
A pyridopyrimidinone derivative as represented by formula I, and a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt thereof or a prodrug thereof. The pyridopyrimidinone derivative has a good SOS1 inhibit...  
WO/2022/165607A1
An oral film dosage form with high loading of active pharmaceutical ingredients, comprising a suspending agent/viscosity increasing agent, a mucoadhesive film former, an amphiphilic solubility enhancer, a non-amphipathic solubility enhan...  
WO/2022/167457A1
The present invention provides compounds of formula (I), compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.  
WO/2022/162992A1
The present invention addresses the problem of providing a new pharmaceutical composition that can treat a T cell-independent reaction or an early phase reaction (a symptom in an early phase) of an allergic disease. Examples of the pre...  
WO/2022/133362A1
Disclosed are facile methods of purifying a cannabis extract to produce highly purified, crystallized cannabinoid acids, and in particular cannabinoid acids such as THCA, and removing impurities from the same, by using polar aprotic solv...  
WO/2022/115879A1
The present disclosure relates to compounds and pharmaceutical compositions thereof, and methods of using the compounds and compositions in therapy, such as methods of treating cancer.  
WO/2022/081742A1
Disclosed herein are methods of treating a complication of a hemoiysis and/or an inflammasome activation-associated disease comprising administering to a patient in need thereof quinine, or a derivative or sait thereof, or the combinatio...  
WO/2022/069509A1
The present invention relates to novel 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1- yl)-acetamide derivatives as potent inhibitors of transforming growth factor-β receptor I, (also named activin receptor-like kinase 5) (TGFβRI)/ALK5. O...  
WO/2022/017519A1
A quinazoline compound and a pharmaceutically acceptable salt thereof, in particular a compound of formula (II) and a pharmaceutically acceptable salt thereof.  
WO/2021/261498A1
A composition which contains a cyclic ether component, a thiol component, and a compound represented by general formula (1). It is preferable that the content of the cyclic ether component is from 20 parts by mass to 80 parts by mass in ...  
WO/2021/260029A1
The present invention relates in its broadest aspect to a compound of Formula I as provided herein, formulations comprising such a compound and corresponding uses thereof for the reduction of infestation with ectoparasites, in particular...  
WO/2021/261497A1
The present invention provides a compound represented by general formula (1). (In the formula, Ar is an aromatic ring group having two or more ring structures, A is a group having a quinuclidine skeleton, B- is a monovalent anion, and R1...  
WO/2021/228673A1
The invention relates to a process for preparing optically enriched isoxazoline compounds of formula (I) wherein the variables are as defined in the specification, and the shown enantiomer has at least 75% ee; by oxo-Michael addition of ...  
WO/2021/218833A1
The main purpose of the present invention is to provide a novel crystal of a quaternary ammonium salt structure compound, i.e., (2R,3R)-3-[(2-cyclopentyl-2-hydroxy-2-phenyl)ethoxy]-1-(3-ph enoxypropyl)-1-azabicyclo[2,2,2]octylonium bromi...  
WO/2021/215537A1
The present invention addresses the problem of providing a 2-heteroarylaminoquinazolinone derivative. The present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof [in the formula, X1 ...  
WO/2021/172359A1
Provided is a novel CDK9 inhibitor prodrug and a liposome that includes the same. The present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof, and a liposome that includes the same. ...  
WO/2021/158948A1
The disclosure includes compounds of Formula (I) and Formula(A) wherein R1, R2, R3, m, n, k, and L are defined herein. Also disclosed are methods for treating a neoplastic disease, autoimmune disease, or an inflammatory disorder with the...  
WO/2021/158640A1
The claimed invention refers to a crystalline form B of 3-((lR,5S,9r) -9-ethoxy-3-azabicyclo[3.3.1]nonan-9-yl)-benzamide hydrochloride as mu-opioid receptor (MOR) agonist for the treatment of pain. (I) The crystalline form B is character...  
WO/2021/113365A1
Lipid nanoparticle compositions for delivery of nucleic acids are described. The lipid nanoparticle may contain a conformationally constrained ionizable lipid as part of the composition. These compositions may allow for delivery of cargo...  
WO/2021/032934A1
The present invention provides compounds of formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, B, and, n, are as defined herein.  
WO/2021/013800A1
The invention relates to substituted N-phenyl-N-aminouracils of general formula (I) or salts thereof, wherein the groups in general formula (I) are as defined in the description, and to the use thereof as herbicides, in particular for co...  
WO/2021/000041A1
The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) Wherein R1 includes an amino group. These compounds are particularly useful in the formulation and in vivo and ex vivo delivery ...  
WO/2020/263994A1
The present invention discloses a liquid, propellant-free pharmaceutical formulation and a method for administering a pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutic...  
WO/2020/252589A1
The present document describes compounds, or pharmaceutically acceptable salt thereof, of a core formula (I) where R1 features an amine group, particularly useful in the formulation of lipid particles including nucleic acid therapeutic a...  
WO/2020/248076A1
Disclosed are methods for separating, recovering, and purifying cannabidiolic acid (CBDA) salts from an organic solvent solution comprising a mixture of cannabinoids. The methods comprise solubilizing the mixture of cannabinoids in C5-C7...  
WO/2020/248077A1
Disclosed are methods for separating, recovering, and purifying tetrahydrocannabinolic acid (THCA) salts from an organic solvent solution comprising a mixture of cannabinoids. The methods comprise solubilizing the mixture of cannabinoids...  
WO/2020/252222A1
Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal dementia (FTD).  
WO/2020/216766A1
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra2, Ra4, Ra5, Ra6, Ra7, X1, X1a, A1 and A2 have the meaning...  
WO/2020/117637A1
The present invention is directed to derivatives and prodrugs of quinuclidine-ring containing compounds. The present invention is further directed to ophthalmo!ogical compositions comprising a therapeutically effective amount of a compou...  
WO/2020/096909A1
Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3'R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methox y-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3'-yl ester di-hydrochloride salt. Provi...  
WO/2020/096911A1
Provided herein are methods of producing the trihydrate form of (3S, 4R, 3'R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methox y-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3'-yl ester di-hydrochloride salt.  
WO/2020/058458A1
The invention relates to certain substituted quinuclidine-3-one compounds for use in the treatment of hyperproliferative disease, such as cancer, and diseases associated with inflammation. More particularly, the present invention relates...  
WO/2020/039092A2
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/039094A1
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/039088A2
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...  
WO/2020/001304A1
The present invention falls within the field of medical technology, and in particular relates to a compound as shown in formula (I), and a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1, R2, X1, X2, X3, M, Ar...  
WO/2019/243850A1
This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions...  
WO/2019/236699A1
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in th...  
WO/2019/223704A1
Provided are a class of fused-cyclic pyrazolone formamide compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided is a compound having the structure as shown in formula (I) (w...  
WO/2019/182938A1
Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to incr...  
WO/2019/173806A1
A method of treating a cancer in a patient includes obtaining a sample from the patient, using a C-circle assay to detect a presence of an alternative lengthening of telomeres (ALT) phenotype in the sample, and administering an effect am...  
WO/2019/152946A1
Provided herein are compounds that are useful in the treatment of pain in a subject.  
WO/2019/121691A1
The present disclosure relates to compounds of Formula (I): (I) and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for...  
WO/2019/126253A1
Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmace...  
WO/2019/122129A1
The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds...  
WO/2019/126081A1
N-oxides, or salts thereof, wherein G, L2, R1, R5, R9, R10, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions...  
WO/2019/126113A1
Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, an...  
WO/2019/118799A1
Disclosed are compounds of Formula (I) (I) N-oxides, or salts thereof, wherein R1, G, A, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9...  
WO/2019/118528A1
Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemperal dementia (FTD).  
WO/2019/110521A1
The present invention relates to fluorophenyl substituted muscarinic receptor ligands with selectivity for M3 over M2 and to the use of these compounds in the treatment of various diseases such as asthma, chronic obstructive pulmonary di...  

Matches 1 - 50 out of 2,314